Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
Novo Nordisk A/S
This trial is conducted in Africa, Europe, North and South America and Oceania. The aim of
this trial is to compare the effect and safety on blood glucose control in pregnant women
with type 1 diabetes of a modern insulin analogue (insulin detemir) and human insulin (NPH
insulin) given as long-acting insulin in combination with a short-acting insulin (insulin
Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes
Eli Lilly and Company
The purpose of this study is to examine the efficacy and safety of insulin lispro protamine
suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime
insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for
sequentially testing the secondary objectives.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.